# HealthTech and Nutrition Apps Market Research Report - Brazil

**Generated on:** 2026-03-03 12:24:41.880378  
**Industry:** HealthTech and Nutrition Apps  
**Geography:** Brazil  
**Details:** Market analysis of SaaS and mobile apps designed for patients undergoing GLP-1 agonist treatments (Ozempic, Wegovy, Mounjaro). Specific focus on nutritional monitoring, particularly protein intake tracking to prevent muscle mass loss (sarcopenia), and side-effect management. Identify the market size and growth in Brazil, consumer behavior of GLP-1 users regarding nutrition, key competitors (general diet apps vs. specialized digital therapeutics), and whitespace opportunities for treatment adherence and AI-assisted dietary tracking.

---

# Brazil’s GLP-1 Digital Nutrition Moment: Protein-First Apps at the Patent Cliff

## Executive Summary

The Brazilian market for GLP-1 receptor agonists is on the precipice of a massive volume shock. With the core patent for semaglutide (Ozempic/Wegovy) expiring on March 20, 2026 [1] [2], and local pharmaceutical giants like EMS, Biomm, and Hypera Pharma preparing generic launches, prices are expected to drop by 30% to 50% [3] [2]. This "Semaglutide Cliff" will transform GLP-1 therapies from a premium, out-of-pocket luxury into a mainstream chronic disease management tool, driving the active user base to an estimated 5.5 million by 2027 [4]. 

However, this rapid adoption exposes a critical clinical gap: **sarcopenia (muscle loss) and severe gastrointestinal side effects**. Clinical trials reveal that up to 40% of the weight lost on semaglutide is lean mass [5] [6]. To combat this, clinical guidelines mandate a high-quality protein intake of 1.2–1.5 g/kg/day [7] [8]. Brazilian consumers are already signaling demand for digital support, with 33% of GLP-1 users actively seeking personalized meal-planning apps tailored to their specific nutritional needs [9] [10]. 

Currently, generalist diet apps (like MyFitnessPal and Dietbox) lack the specialized titration tracking and per-meal leucine coaching required for GLP-1 patients. Meanwhile, early specialized apps (like OzemPro) lack deep payer integration and clinical evidence. The whitespace opportunity lies in building a **"GLP-1 Protein Co-Pilot"**—an AI-assisted, culturally localized (PT-BR) digital therapeutic that bundles with dominant pharmacy channels (like RD Saúde) and payer Patient Support Programs (PSPs) to drive adherence, preserve lean mass, and capture a rapidly expanding Total Addressable Market (TAM).

## Market Context — GLP-1 Access is Pivoting from Scarcity to Scale

Patent expiry and aggressive local manufacturing investments will expand Brazil’s GLP-1 user base and unlock a step-change in demand for digital nutrition and adherence support.

### Patent Cliff and Capacity Investments
The defining market event is the expiration of the core patent for semaglutide in Brazil on March 20, 2026, following the Superior Court of Justice's (STJ) denial of Novo Nordisk's extension request [1] [2]. In response, massive capital is flowing into local production:
* **Novo Nordisk**: Investing R$ 6.4 billion (USD 1.09 billion) to expand its Montes Claros facility to defend its market share [11] [12].
* **EMS**: Invested over R$ 1 billion in a local peptide platform, already producing liraglutide and preparing for immediate semaglutide generic launch [1] [13].
* **Biomm**: Invested R$ 800 million in a Nova Lima facility and secured an exclusive license with Biocon for vertically integrated semaglutide [1] [13].

### Market Size and Growth Trajectory
The Brazil GLP-1 receptor agonist market generated USD 705.7 million in 2025 and is projected to reach USD 1,727.1 million by 2033, growing at a CAGR of 10.8% [14]. However, volume-driven projections suggest the broader market for slimming pens could reach R$ 20 billion by 2026 [15]. The specific weight-loss treatment segment is projected to reach USD 531.5 million by 2030 [16].

### Channel Dynamics and Digital Retail
Retail chains currently account for 61.24% of GLP-1 sales [3]. RD Saúde (RaiaDrogasil) dominates with a 16.8% national market share and 30.3% in São Paulo [17]. Digital channels are critical, representing 26.7% of RD Saúde's retail sales, with mobile apps driving 81% of online transactions [17]. Furthermore, e-commerce and tele-pharmacy are forecast to grow at a 12.79% CAGR through 2031 [3].

### Patient Mix Shift
While Type 2 Diabetes has historically driven the market, obesity prescriptions are accelerating rapidly. Brazilian endocrinologists report 30% to 40% higher 12-month persistence for once-weekly regimens (like semaglutide) compared to daily options [3]. Private insurers in São Paulo and Rio de Janeiro logged a 45% annual jump in once-weekly GLP-1 scripts in 2025 [3].

## Clinical Imperative — Protein-First to Prevent Sarcopenia

Preserving muscle during rapid weight loss is the primary unmet clinical need; digital solutions can operationalize these guidelines at scale.

### Lean Mass Loss Evidence
GLP-1 therapies induce substantial loss of lean body mass (LST). In the STEP 1 trial for semaglutide, participants lost approximately 40% of their total weight as lean mass [5] [6]. In the SURMOUNT-1 trial for tirzepatide, LST loss accounted for approximately 26% of total weight lost [18]. Liraglutide has been associated with up to 60% lean mass loss in some studies [5].

### Protein Targets and Distribution
To mitigate sarcopenia, expert consensus (ESPEN/EASO) recommends a high-quality protein intake of 1.2–1.5 g/kg of body weight per day [7] [8]. For older adults, guidelines specify 25–30 g of protein at main meals, containing at least 2,500–2,800 mg of leucine per meal to trigger muscle protein synthesis [19]. Digital apps must map these targets to Brazilian food composition tables (TBCA/TACO) [20] [21].

### Resistance Training Protocols
Resistance training is essential for preserving muscle mass and improving strength during weight loss [5] [22]. The American College of Sports Medicine advises strength training at least twice a week on nonconsecutive days, utilizing 8–12 repetitions at ~65% of the individual’s one-repetition maximum [22]. The S-LiTE trial demonstrated that combining liraglutide with structured exercise preserves lean mass significantly better than the drug alone [23].

### Side-Effect Playbook
Gastrointestinal adverse events (nausea, vomiting, diarrhea, constipation) affect up to 70–85% of patients and are a primary cause of treatment discontinuation [24]. Fatigue is also reported with a frequency of >0.4%, which can hinder exercise adherence [25]. Nutritional strategies, including adequate hydration, dietary fiber, and probiotics, are critical for enhancing tolerability [24].

## Consumer Insight — What GLP-1 Users in Brazil Want Now

Users seek protein-centric, portion-smart tools, and they are willing to reallocate food savings toward health-supportive digital subscriptions.

### Demand Signals and Feature Preferences
A February 2026 Kantar study revealed strong demand for digital and nutritional innovations among GLP-1 users [9] [10]:
* **33%** desire personalized meal-planning apps tailored to GLP-1 nutritional needs.
* **28%** want high-protein, low-calorie desserts.
* **24%** are interested in smart portion-control plates and silverware.
* **24%** seek hydration beverages with added electrolytes and collagen.

### Behavior Shifts and Willingness-to-Pay
GLP-1 users are shifting away from restaurant dining toward home meal preparation [9]. Because self-pay costs for these medications average approximately USD 1,000 per month [26], users often justify the expense through a "food-cost offset"—the money saved on reduced food consumption is redirected toward the medication and supporting wellness tools [27].

## Competitive Landscape — Generalists vs. GLP-1 Specialists

While generalist apps have added basic GLP-1 content, specialized apps are capturing users by addressing specific medication workflows. Defensibility will require clinical depth, integrations, and B2B2C distribution.

### Generalist Apps in Brazil: GLP-1 Relevance Snapshot

| App | Localization | GLP-1 Specific Features | Gaps for GLP-1 Users |
| :--- | :--- | :--- | :--- |
| **MyFitnessPal** | PT-BR | Dedicated GLP-1 Nutrition Plan; macro tracking; Apple/Google Fit sync [28] [29]. | Lacks injection site rotation; side-effect guidance is content-only, not interactive triage. |
| **Yazio** | PT-BR | AI photo food scanning; intermittent fasting timers [30] [31]. | No titration tracking; no specific GLP-1 side-effect management. |
| **Dietbox** | PT-BR | Dietitian-linked plans; hydration alerts; direct chat with professionals [32] [33]. | Requires a linked nutritionist; patient app is a companion tool, not a standalone tracker. |
| **Nutrium** | PT-BR | Corporate wellness (Nutrium Care); digital meal plans [34] [35]. | B2B/Professional focus; lacks automated AI food logging for independent users. |

*Takeaway*: Generalist apps excel at broad calorie counting but fail to provide the per-meal leucine targets, injection protocols, and automated side-effect triage required by GLP-1 patients.

### Specialized GLP-1 Apps: Feature and Localization Comparison

| App | Localization | Key Features | Pricing & Distribution |
| :--- | :--- | :--- | :--- |
| **OzemPro** | PT-BR | Injection/site rotation; AI photo/barcode logging for protein/fiber; symptom log; 4.8 stars [36] [37]. | Subscription-only; B2C app store distribution [38]. |
| **GLP AI** | PT-BR | Injection tracker; AI nutrition scanner; 24/7 AI coach trained on GLP-1 protocols [39]. | Subscription with 3-day free trial [39]. |
| **MetaCurve** | 15+ Languages | Multi-brand support; side-effect analytics; 100% on-device privacy [40]. | Freemium/Premium trial [40]. |
| **Oz App** | PT-BR | Injection reminders; educational videos; Novo Nordisk official app [41]. | Free; distributed as a Patient Support Program (PSP) tool [41]. |

*Takeaway*: Specialized apps are winning on UX (injection tracking, AI protein scanning), but they currently lack clinical evidence (RWE), payer integration, and advanced sarcopenia screening (e.g., BIA integration).

## Regulatory & Reimbursement Map — Build for Wellness, Architect for SaMD

To move fast, new entrants should launch as wellness applications with rigorous safety guardrails, while architecting the backend to achieve Software as a Medical Device (SaMD) certification within 12–18 months.

### SaMD vs. Wellness Classification
Under ANVISA RDC 657/2022 and RDC 751/2022, software that performs risk classification or suggests medications based on clinical protocols is classified as a Medical Device (SaMD) [42] [43] [44]. Apps that strictly provide nutrition education and tracking without diagnostic claims can operate as wellness tools, avoiding immediate Class II/III registration hurdles.

### GLP-1 Policy Specifics
ANVISA has tightened controls on GLP-1s. Order No. 97/2025 restricts the importation of GLP-1 APIs for compounding pharmacies to curb illicit trade [45] [46]. Furthermore, GLP-1s now require retained digital prescriptions [47]. RDC 848/2024 governs the pen injector devices, which remains a bottleneck for generic entry [1].

### Telehealth and Data Privacy (LGPD)
Federal Law 14,510/2022 regulates telehealth, allowing remote dietitian support and e-prescriptions using ICP-Brasil digital signatures [48] [49] [50]. Brazil's General Data Protection Law (LGPD) classifies health data as sensitive, requiring express consent, data minimization, and human-in-the-loop processes for automated AI decisions [51] [52].

## Product & Technology Blueprint — Protein AI and Titration-Aware UX

A multimodal, PT-BR AI stack combined with rule-based safety is the shortest path to achieving outcomes and compliance in Brazil.

### AI/ML Stack and Data Localization
The core feature must be an AI food scanner optimized for Brazilian cuisine. This requires mapping computer vision models to the TBCA-USP (Tabela Brasileira de Composição de Alimentos), which contains over 3,400 regional foods and specific protein conversion factors [20] [21]. Barcode scanning should integrate with GS1 Brasil and Open Food Facts [53]. LLM-based coaching must be fine-tuned in native Brazilian Portuguese to capture regional nuances and avoid translation errors [54].

### UX and Safety Guardrails
The UX must center on **per-meal protein and leucine tiles**, guiding users to hit the 25–30g threshold per meal. It should include dose-synced prompts (e.g., hydration reminders 24 hours post-injection) and titration timelines. Safety guardrails must include rule-based triage for GI symptoms, escalating severe cases (e.g., signs of cholelithiasis or severe dehydration) to a human clinician or tele-nutritionist.

### Integrations and Privacy-by-Design
The app should sync with Apple Health and Google Fit for wearable data (steps, resistance training logging) [29]. Future-proofing requires readiness for the National Health Data Network (RNDS) using HL7 FHIR standards [55] [56]. To comply with LGPD, the architecture should utilize on-device processing where possible, end-to-end encryption, and strict data minimization [57].

## Go-to-Market & Partnerships — Win via Pharmacy and Payer PSPs

While B2C app store distribution proves initial traction, scaling requires B2B2C bundling through pharmacies and payers.

### Pharmacy Channel Playbook
Retail pharmacies control the GLP-1 market. Partnering with dominant chains offers immediate distribution.

| Partner Type | Key Assets | Bundle Concept | Target KPIs |
| :--- | :--- | :--- | :--- |
| **RD Saúde** | 3,400+ stores; Vitat wellness platform; Cuco Health (B2B adherence); Stix loyalty [17] [58]. | "GLP-1 Nutrition Pack": App access + bioimpedance scale + Vitat dietitian chat. | Bundle attach rate (35-50%); Stix redemption; Refill adherence. |
| **Pague Menos / DPSP** | High regional penetration; in-store clinic rooms. | Point-of-sale QR code onboarding with first-month free trial. | Cost of Acquisition (CAC) reduction; Day-30 retention. |

### Pharma PSPs and Payers
Manufacturers like Novo Nordisk, Eli Lilly, and EMS are highly incentivized to improve medication adherence. Integrating the app into existing Patient Support Programs (PSPs) via platforms like Cuco Health can secure manufacturer subsidies [58]. For private payers (ANS regulated plans like SulAmérica, Amil, Bradesco) [59], the pitch is value-based care: reducing ER visits for GI side effects and preventing long-term sarcopenia complications.

## Business Model & Unit Economics — Price to Attach, Scale via B2B2C

Blend accessible B2C pricing with pharmacy/payer subsidies, keeping gross margins high through AI-first operations.

### Pricing Benchmarks
* **B2C**: Specialized GLP-1 trackers globally charge around USD 19.99 to 39.99 annually (approx. R$ 100 - R$ 200) [60] [61]. Local apps like OzemPro operate on strict subscription models without free tiers [38].
* **B2B2C**: Payer pilots should target Per-Member-Per-Month (PMPM) fees, potentially structured with outcomes bonuses (e.g., base PMPM + bonus if >20% lean body mass is preserved).

### CAC and Cost-to-Serve
Acquiring users through pharmacy partnerships and HCP referrals significantly lowers Customer Acquisition Cost (CAC) compared to paid social media ads. The cost-to-serve must be managed by relying on AI for daily logging and triage, reserving expensive human dietitian time for escalated cases or premium subscription tiers.

## Evidence & Outcomes — Pragmatic RWE for Payer-Grade Claims

To win lucrative payer contracts, the app must prove it protects body composition and improves medication persistence.

### Trial Design
Launch a 16-week pragmatic Real-World Evidence (RWE) study targeting ~300 GLP-1 initiators. 
* **Endpoints**: Appendicular Lean Mass (ALM) via Bioelectrical Impedance Analysis (BIA) or DEXA, handgrip strength, Short Physical Performance Battery (SPPB), and 6-month medication persistence.
* **Goal**: Prove that app users hit the 1.2 g/kg/day protein target and retain significantly more lean mass than the control group. Publish findings in Brazilian clinical journals (e.g., BRASPEN) to build a dossier for ANS health plans.

## Risk Map & Mitigations

Design for supply, security, and regulatory volatility from day one.

* **Supply/Device Bottlenecks**: The global shortage of pen injectors limits generic scalability [1]. *Mitigation*: Build a multi-SKU, brand-agnostic app that supports users regardless of which GLP-1 brand they can source.
* **Theft and Counterfeits**: Cargo theft (R$ 70M lost in SP) and illegal compounding are rampant [1]. *Mitigation*: Integrate with pharmacy pickup flows and validate prescription authenticity to ensure users are taking legitimate medication.
* **Privacy Compliance**: LGPD violations carry heavy fines. *Mitigation*: Conduct Data Protection Impact Assessments (DPIA) and ensure AI models do not hallucinate medical advice [51].

## TAM/SAM/SOM & Scenarios — Quantifying Adoption

The base case supports a Serviceable Addressable Market (SAM) of 0.9 to 1.6 million users within 24 months.

* **Inputs**: Itaú estimates 5.5 million active GLP-1 users in Brazil by 2027 [4]. Brazil has ~50 million private insured lives and >85% smartphone penetration [3] [62].
* **Conservative Scenario**: 10–15% B2C adoption among new generic users. Focus on basic tracking and organic app store growth.
* **Base Scenario**: 25–30% adoption. Achieved by securing a major pharmacy bundle (e.g., RD Saúde) that captures users at the point of sale.
* **Accelerated Scenario**: 45–55% adoption. Achieved by integrating into payer PSPs and value-based care models, where the app is prescribed alongside the medication.

## Product Roadmap — 24 Months to Defensibility

* **0–6 Months**: Launch PT-BR computer vision food logger mapped to TBCA/TACO. Deploy injection tracker, titration-aware prompts, and rule-based GI triage. Secure a pilot with a major pharmacy chain.
* **6–12 Months**: Roll out resistance training programs and per-meal leucine targets. Partner with diagnostic labs (e.g., Fleury/Dasa) for BIA data ingestion. Complete the 16-week RWE study.
* **12–24 Months**: Utilize RWE data to secure SaMD-lite claims. Launch PMPM pilots with top-tier ANS health plans. Achieve RNDS/FHIR interoperability for seamless EHR integration.

## References

1. *Brazilian Pharmaceuticals 2026: The Innovation & Patent Cliff Frontier - DrugPatentWatch – Transform Data into Market Domination*. https://www.drugpatentwatch.com/blog/brazilian-pharmaceuticals-a-new-frontier-in-innovation-and-medicine/
2. *STJ barra extensão de patente do Ozempic: o que muda para pacientes, SUS e mercado de genéricos? | G1*. https://g1.globo.com/saude/noticia/2025/12/17/stj-barra-extensao-de-patente-do-ozempic-o-que-muda-para-pacientes-sus-e-mercado-de-genericos.ghtml
3. *Latin America Glucagon-like Peptide-1 Agonists Market - GLP-1 - Size, Share & Analysis*. https://www.mordorintelligence.com/industry-reports/latin-america-glucagon-like-peptide-1-agonists-market
4. *Weight-loss drugs ripple through Brazil's food industry*. https://valorinternational.globo.com/business/news/2026/02/18/weight-loss-drugs-ripple-through-brazils-food-industry.ghtml
5. *Changes in lean body mass with glucagon‐like peptide‐1‐based therapies and mitigation strategies - Neeland - 2024 - Diabetes, Obesity and Metabolism - Wiley Online Library*. https://dom-pubs.onlinelibrary.wiley.com/doi/10.1111/dom.15728
6. *Nutrition support whilst on glucagon-like peptide-1 based therapy. Is it necessary? - PubMed*. https://pubmed.ncbi.nlm.nih.gov/40401903/
7. *
            Nutritional and lifestyle supportive care recommendations for management of obesity with GLP-1 - based therapies: An expert consensus statement using a modified Delphi approach - PMC
        *. https://pmc.ncbi.nlm.nih.gov/articles/PMC12768930/
8. *Nutrition Strategies for Next‐Generation Incretin Therapies*. https://onlinelibrary.wiley.com/doi/10.1111/obr.70079
9. *GLP 1 at scale: What rapid adoption means for consumers and brands*. https://www.kantar.com/north-america/inspiration/research-services/global-glp1-adoption-for-consumers-and-brands
10. *7 inovações que usuários de GLP-1 gostariam de ver no mercado*. https://www.kantar.com/brazil/inspiration/7-inovacoes-que-usuarios-de-glp1-gostariam-de-ver-no-mercado
11. *Novo Nordisk to invest $1.09 billion to boost Ozempic, Wegovy production in Brazil | Reuters*. https://www.reuters.com/business/healthcare-pharmaceuticals/novo-nordisk-invest-109-billion-increase-production-brazil-2025-04-07/
12. *Novo Nordisk anuncia investimento de R$ 6,4 bilhões na expansão da sua fábrica em Montes Claros-MG*. https://www.novonordisk.com.br/noticias-e-imprensa/busca-noticias/novo-nordisk-anuncia-investimento-de-6-bilhoes-na-expansao-da-sua-fabrica-em-montes-claros.html
13. *Brazilian drugmakers move into weight-loss injection market*. https://valorinternational.globo.com/business/news/2026/01/13/brazilian-drugmakers-move-into-weight-loss-injection-market.ghtml
14. *Brazil GLP-1 Receptor Agonist Market Size & Outlook, 2033*. https://www.grandviewresearch.com/horizon/outlook/glp-1-receptor-agonist-market/brazil
15. *
            Anvisa accelerates analysis of slimming pens similar to Ozempic. - NeoFeed        *. https://neofeed.com.br/negocios/anvisa-acelera-analise-de-canetas-emagrecedoras-similares-ao-ozempic/en/
16. *Brazil Pharma Diabetes and Weight-Loss Drugs*. https://www.trade.gov/market-intelligence/brazil-pharma-diabetes-and-weight-loss-drugs
17. *Raia Drogasil Posts Double-Digit Growth as Digital and GLP-1 Drugs Drive Q3 Surge - Brazil Stock Guide*. https://brazilstockguide.com/insights/raia-drogasil-q3-2025-results-profit-digital-glp1/
18. *Preservation of lean soft tissue during weight loss induced by ...*. https://pmc.ncbi.nlm.nih.gov/articles/PMC12536186/
19. *
            Protein and Leucine Intake at Main Meals in Elderly People with Type 2 Diabetes - PMC
        *. https://pmc.ncbi.nlm.nih.gov/articles/PMC10053961/
20. *Brazilian Table of Composition Foods.*. https://www.tbca.net.br/indexen.html
21. *(PDF) Tabela Brasileira de Composição de Alimentos TBCA-USP (Versões 3 e 4) no contexto internacional*. https://www.researchgate.net/publication/237759233_Tabela_Brasileira_de_Composicao_de_Alimentos_TBCA-USP_Versoes_3_e_4_no_contexto_internacional
22. *Treating Sarcopenic Obesity in the Era of Incretin Therapies: Perspectives and Challenges | Diabetes | American Diabetes Association*. https://diabetesjournals.org/diabetes/article/74/12/2179/160535/Treating-Sarcopenic-Obesity-in-the-Era-of-Incretin
23. *
            Optimizing GLP-1 therapies for obesity and diabetes management - PMC
        *. https://pmc.ncbi.nlm.nih.gov/articles/PMC12661421/
24. *Nutritional Approaches to Enhance GLP-1 Analogue Therapy in Obesity: A Narrative Review*. https://www.mdpi.com/2673-4168/5/4/88
25. *Muscle Mass and Glucagon-Like Peptide-1 Receptor Agonists: Adaptive or Maladaptive Response to Weight Loss? | Circulation*. https://www.ahajournals.org/doi/10.1161/CIRCULATIONAHA.124.067676
26. *Obesity GLP-1 Market*. https://www.futuremarketinsights.com/reports/obesity-glp-1-market
27. *
            Beyond the prescription: Global observations on the social implications of GLP-1 receptor agonists for weight loss - PMC
        *. https://pmc.ncbi.nlm.nih.gov/articles/PMC12742762/
28. *Nutrition app MyFitnessPal announces tools for GLP-1 medication support | MobiHealthNews*. https://www.mobihealthnews.com/news/nutrition-app-myfitnesspal-announces-tools-glp-1-medication-support
29. *MyFitnessPal: Calorie Counter - Apps on Google Play*. https://play.google.com/store/apps/details?id=com.myfitnesspal.android&hl=en_US
30. *Healthy Weight Loss & Eating: Lose Weight Fast with YAZIO*. https://www.yazio.com/en
31. *Fetched web page*. https://www.yazio.com/pt
32. *‎Dietbox App - App Store*. https://apps.apple.com/us/app/dietbox/id648610153
33. *Dietbox - Apps on Google Play*. https://play.google.com/store/apps/details?id=com.craftbox.dietbox&hl=en_US
34. *Nutrium – Apps no Google Play*. https://play.google.com/store/apps/details?id=co.healthium.nutrium&hl=pt
35. *Fetched web page*. https://nutrium.com/pt-br/
36. *OzemPro: Diário de Saúde - Apps on Google Play*. https://play.google.com/store/apps/details?id=com.segaritz.ozempro&hl=en_US
37. *‎App OzemPro: Monitor GLP-1 – App Store*. https://apps.apple.com/br/app/ozempro-monitor-glp-1/id6753301974
38. *‎App OzemPro: Monitor GLP-1 – App Store*. https://apps.apple.com/us/app/ozempro-monitor-glp-1/id6753301974?l=pt-BR
39. *‎App GLP AI: Ozempic Mounjaro – App Store*. https://apps.apple.com/br/app/glp-ai-ozempic-mounjaro/id6755669956
40. *MetaCurve-Weight Loss Buddy – Apps no ...*. https://play.google.com/store/apps/details?id=tr.com.physiotr.metacurve&hl=pt
41. *Oz – Apps no Google Play*. https://play.google.com/store/apps/details?id=com.novonordisk.SemaChatbotPH&hl=pt_PT
42. *Anvisa approves new regulatory framework for Software as ...*. https://www.mattosfilho.com.br/en/unico/anvisa-approves-regulatory-software-medical/
43. *Brazil Medical Device Regulations - ANVISA RDC 751/2022*. https://qservegroup.com/en/brazil-medical-device-regulations
44. *Resolução da Diretoria Colegiada - RDC nº 657, de 24/03/2022*. https://anvisalegis.datalegis.net/action/ActionDatalegis.php?acao=abrirTextoAto&tipo=RDC&numeroAto=00000657&seqAto=000&valorAno=2022&orgao=RDC/DC/ANVISA/MS&codTipo=&desItem=&desItemFim=&cod_menu=9434&cod_modulo=310&pesquisa=true
45. *ANVISA altera regras de importação de liraglutida, semaglutida e tirzepatida para manipulação magistral - Lexology*. https://www.lexology.com/library/detail.aspx?g=c7d01e80-d446-442b-ba62-57f468f666f1
46. *Despacho ANVISA Nº 97 DE 22/08/2025 - Federal - LegisWeb*. https://www.legisweb.com.br/legislacao/?id=482615
47. *
    
    Wegovy, Ozempic, Mounjaro Now Require Retained Prescriptions in Brazil
  
  *. https://www.mybraziliandoctor.com.br/wegovy-ozempic-mounjaro-now-require-retained-prescriptions-in-brazil
48. *How is telehealth regulated? in Brazil - DLA Piper Telehealth Around the World*. https://www.dlapiperintelligence.com/telehealth/countries/brazil/02-regulation-of-telehealth.html
49. *L14510 - Planalto*. https://www.planalto.gov.br/ccivil_03/_ato2019-2022/2022/lei/l14510.htm
50. *RESOLUÇÃO CFM Nº 2.299/2021*. https://sistemas.cfm.org.br/normas/arquivos/resolucoes/BR/2021/2299_2021.pdf
51. *
	    AI and digital health in Brazil: balancing innovation and regulation   | International Bar Association*. https://www.ibanet.org/ai-digital-health-brazil
52. *
	    The protection of health data in Brazil  | International Bar Association*. https://www.ibanet.org/protections-health-data-brazilds
53. *Add an API for country detection using GS1 Barcode prefixes · Issue #409 · openfoodfacts/openfoodfacts-server · GitHub*. https://github.com/openfoodfacts/openfoodfacts-server/issues/409
54. *Assessing the User Experience of an LLM-Based ... - PMC*. https://pmc.ncbi.nlm.nih.gov/articles/PMC12872950/
55. *An experience of exchange health data using FHIR*. https://repositorio.unip.br/wp-content/uploads/tainacan-items/198/64307/eng_neusa_maria_andrade.pdf
56. *brazilian-patient-summary-exchange-health-data-using-ips ...*. https://www.hilarispublisher.com/open-access/brazilian-patient-summary-exchange-health-data-using-ips-and-fhir.pdf
57. *What Is the LGPD? Brazil's Data Protection Law Explained ...*. https://www.accountablehq.com/post/what-is-the-lgpd-brazil-s-data-protection-law-explained-with-best-practices-and-compliance-tips
58. *Annual and Sustainability*. https://rdsaude.com.br/wp-content/uploads/2024/04/b5226ff1-rd_relat2022_en_06062023_vf_emendado_reshi_05.07.23.pdf
59. *Sulamérica, Amil e Bradesco lideram expansão de planos de saúde*. https://oespecialista.safra.com.br/analise/sul11-amil3-planos-de-saude/
60. *GLP-1 Tracker: Pep - App Store - Apple*. https://apps.apple.com/us/app/glp-1-tracker-pep/id6504788281
61. *Glp-1 Weight Loss Shot Tracker - App Store - Apple*. https://apps.apple.com/us/app/glp-1-weight-loss-shot-tracker/id6756852361
62. *Latin America Digital Health Market Growth & Analysis, 2033*. https://www.marketdataforecast.com/market-reports/latin-america-digital-health-market